Pivotal Study of rhBMP-2/ACS/LT-CAGE® Device for Anterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease
Primary Purpose
Degenerative Disc Disease
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
rhBMP-2/ACS/LT-CAGE® Device
Autogenous Bone/LT-CAGE® Device
Sponsored by
About this trial
This is an interventional treatment trial for Degenerative Disc Disease focused on measuring symptomatic degenerative disc disease
Eligibility Criteria
Inclusion Criteria:
Has degenerative disc disease as noted by back pain of discogenic origin, with or without leg pain, with degeneration of the disc confirmed by patient history ( e.g.,pain [leg, back, or symptoms in the sciatic nerve distribution], function deficit and/or neurological deficit) and radiographic studies ( e.g., CT, MRl, X-Ray, etc.) to include one or more of the following:
- instability (defined as angular motion > 5° and/or translation >= 4mm, based on Flex/Ext radiographs);
- osteophyte formation;
- decreased disc height;
- thickening of ligamentous tissue;
- disc degeneration or herniation; and/or
- facet joint degeneration.
- Has preoperative Oswestry score > 35.
- Has no greater than Grade 1 spondylolisthesis utilizing Meyerding's Classification (Meyerding HW, 1932.).
- Has single-level symptomatic degenerative involvement from L4 to S1.
- Is at least 18 years of age, inclusive, at the time of surgery.
- Has not responded to non-operative treatment (e.g., bed rest, physical therapy, medications, spinal injections, manipulation, and/or TENS) for a period of at least 6 months.
- If female of child-bearing potential, who is not pregnant or nursing, and who agrees to use adequate contraception for 16 weeks following surgery.
- Is willing and able to comply with the study plan and sign the Patient Informed Consent Form.
Exclusion Criteria:
- Had previous anterior spinal fusion surgical procedure at the involved level.
- Has posterior spinal instrumentation (which will not be removed) stabilizing the involved level or has had a previous posterior lumbar interbody fusion procedure at the involved level.
- Has a condition which requires postoperative medications that interfere with fusion, such as steroids.
- Has been previously diagnosed with osteopenia, osteoporosis, or osteomalacia to a degree that spinal instrumentation would be contraindicated.
- Has presence of active malignancy.
- Has overt or active bacterial infection, either local or systemic.
- ls grossly obese, i.e., weight > 40% over ideal for their age and height.
- Has fever ( temperature > 101° F oral) at the time of surgery.
- Has a documented titanium alloy allergy or intolerance.
- Is mentally incompetent. if questionable, obtain psychiatric consult.
- Has a Waddell Signs of Inorganic Behavior score of 3 or greater.
- Is a prisoner.
- Is an alcohol and/or drug abuser as defined by currently undergoing treatment for alcohol and/or drug usage.
- Is a tobacco user at the time of surgery.
- Has received drugs which may interfere with bone metabolism within two weeks prior to the planned date of spinal fusion surgery (e.g., steroids or methotrexate).
- Has a history of autoimmune disease (Systemic Lupus Erythematosus or Dermatomyositis).
- Has a history of exposure to injectable collagen implants.
- Has a history of hypersensitivity to protein pharmaceuticals (monoclonal antibodies or gamma globulins) or collagen.
- Has received treatment with an investigational therapy within 28 days prior to implantation surgery or such treatment is planned during the 16 weeks following rhBMP-2/ACS implantation.
- Has received any previous exposure to any/all BMP's of either human or animal extraction.
- Has a history of allergy to bovine products or a history of anaphylaxis.
- Has history of endocrine or metabolic disorder known to affect osteogenesis (e.g., Paget's disease, renal osteodystrophy, Ehlers- Danlos syndrome, or osteogenesis imperfecta).
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
rhBMP-2/ACS
Autogenous Bone
Arm Description
Outcomes
Primary Outcome Measures
Overall success
A patient will be considered an overall success if all of the following conditions are met:
fusion;
pain/disability (Oswestry) improvement;
maintenance or improvement in neurological status;
no serious adverse event classified as implant associated or implant/surgical procedure associated;
no additional surgical procedure classified as a "failure."
Secondary Outcome Measures
Disc Height Measurement
General Health Status (SF-36)
Pain Status (Numerical Rating Scale)
Patient Satisfaction
Patient Global Perceived Effect
Full Information
NCT ID
NCT01491386
First Posted
December 12, 2011
Last Updated
May 16, 2023
Sponsor
Medtronic Spinal and Biologics
1. Study Identification
Unique Protocol Identification Number
NCT01491386
Brief Title
Pivotal Study of rhBMP-2/ACS/LT-CAGE® Device for Anterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease
Official Title
A Clinical Investigation of Recombinant Human Bone Morphogenetic Protein-2 and Absorbable Collagen Sponge With the LT-CAGE® Device for Anterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Completed
Study Start Date
August 1998 (undefined)
Primary Completion Date
October 2002 (Actual)
Study Completion Date
October 2002 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medtronic Spinal and Biologics
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study is designed to assess the safety and effectiveness of the rhBMP-2/ACS/LT-CAGE® device as compared to the LT-CAGE® device with autogenous bone in patients with symptomatic degenerative disc disease using an open surgical technique.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Degenerative Disc Disease
Keywords
symptomatic degenerative disc disease
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
279 (Actual)
8. Arms, Groups, and Interventions
Arm Title
rhBMP-2/ACS
Arm Type
Experimental
Arm Title
Autogenous Bone
Arm Type
Active Comparator
Intervention Type
Device
Intervention Name(s)
rhBMP-2/ACS/LT-CAGE® Device
Other Intervention Name(s)
Recombinant human bone morphogenetic protein
Intervention Description
LT-CAGE® device with recombinant human bone morphogenetic protein-2 ( rhBMP-2) and the absorbable collagen sponge (ACS).
Intervention Type
Device
Intervention Name(s)
Autogenous Bone/LT-CAGE® Device
Other Intervention Name(s)
Autograft
Intervention Description
LT-CAGE® device with autogenous bone taken from the iliac crest.
Primary Outcome Measure Information:
Title
Overall success
Description
A patient will be considered an overall success if all of the following conditions are met:
fusion;
pain/disability (Oswestry) improvement;
maintenance or improvement in neurological status;
no serious adverse event classified as implant associated or implant/surgical procedure associated;
no additional surgical procedure classified as a "failure."
Time Frame
24 months
Secondary Outcome Measure Information:
Title
Disc Height Measurement
Time Frame
24 months
Title
General Health Status (SF-36)
Time Frame
24 months
Title
Pain Status (Numerical Rating Scale)
Time Frame
24 months
Title
Patient Satisfaction
Time Frame
24 months
Title
Patient Global Perceived Effect
Time Frame
24 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Has degenerative disc disease as noted by back pain of discogenic origin, with or without leg pain, with degeneration of the disc confirmed by patient history ( e.g.,pain [leg, back, or symptoms in the sciatic nerve distribution], function deficit and/or neurological deficit) and radiographic studies ( e.g., CT, MRl, X-Ray, etc.) to include one or more of the following:
instability (defined as angular motion > 5° and/or translation >= 4mm, based on Flex/Ext radiographs);
osteophyte formation;
decreased disc height;
thickening of ligamentous tissue;
disc degeneration or herniation; and/or
facet joint degeneration.
Has preoperative Oswestry score > 35.
Has no greater than Grade 1 spondylolisthesis utilizing Meyerding's Classification (Meyerding HW, 1932.).
Has single-level symptomatic degenerative involvement from L4 to S1.
Is at least 18 years of age, inclusive, at the time of surgery.
Has not responded to non-operative treatment (e.g., bed rest, physical therapy, medications, spinal injections, manipulation, and/or TENS) for a period of at least 6 months.
If female of child-bearing potential, who is not pregnant or nursing, and who agrees to use adequate contraception for 16 weeks following surgery.
Is willing and able to comply with the study plan and sign the Patient Informed Consent Form.
Exclusion Criteria:
Had previous anterior spinal fusion surgical procedure at the involved level.
Has posterior spinal instrumentation (which will not be removed) stabilizing the involved level or has had a previous posterior lumbar interbody fusion procedure at the involved level.
Has a condition which requires postoperative medications that interfere with fusion, such as steroids.
Has been previously diagnosed with osteopenia, osteoporosis, or osteomalacia to a degree that spinal instrumentation would be contraindicated.
Has presence of active malignancy.
Has overt or active bacterial infection, either local or systemic.
ls grossly obese, i.e., weight > 40% over ideal for their age and height.
Has fever ( temperature > 101° F oral) at the time of surgery.
Has a documented titanium alloy allergy or intolerance.
Is mentally incompetent. if questionable, obtain psychiatric consult.
Has a Waddell Signs of Inorganic Behavior score of 3 or greater.
Is a prisoner.
Is an alcohol and/or drug abuser as defined by currently undergoing treatment for alcohol and/or drug usage.
Is a tobacco user at the time of surgery.
Has received drugs which may interfere with bone metabolism within two weeks prior to the planned date of spinal fusion surgery (e.g., steroids or methotrexate).
Has a history of autoimmune disease (Systemic Lupus Erythematosus or Dermatomyositis).
Has a history of exposure to injectable collagen implants.
Has a history of hypersensitivity to protein pharmaceuticals (monoclonal antibodies or gamma globulins) or collagen.
Has received treatment with an investigational therapy within 28 days prior to implantation surgery or such treatment is planned during the 16 weeks following rhBMP-2/ACS implantation.
Has received any previous exposure to any/all BMP's of either human or animal extraction.
Has a history of allergy to bovine products or a history of anaphylaxis.
Has history of endocrine or metabolic disorder known to affect osteogenesis (e.g., Paget's disease, renal osteodystrophy, Ehlers- Danlos syndrome, or osteogenesis imperfecta).
12. IPD Sharing Statement
Learn more about this trial
Pivotal Study of rhBMP-2/ACS/LT-CAGE® Device for Anterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease
We'll reach out to this number within 24 hrs